• Microba's path to cashflow break-even by CY2027
• Strong sales growth with 11 consecutive quarters of QoQ growth
• Expansion of addressable market to $25B
• Upcoming launch of a category-defining testing product
• Active partnering process for therapeutics division

Microba Life Sciences Ltd has outlined a strategic path to achieve cashflow break-even by the end of calendar year 2027. The company is leveraging its streamlined operations and AI efficiency to reduce costs while maintaining strong sales momentum. Microba has experienced 11 consecutive quarters of growth, with a 106% increase in sales over the last 12 months. The company's addressable market is estimated at $25 billion, targeting 82 million patients annually with gastrointestinal disorders. An upcoming category-defining testing product is set to launch in Q3 CY26, further driving adoption. Additionally, Microba's therapeutics division is in an active partnering process with a Boston-based advisor, following recent positive clinical trial readouts.

Microba Life Sciences Ltd expects to achieve cashflow break-even by CY2027.

Microba Life Sciences Ltd anticipates continued growth in sales and customer adoption, driven by its new product launch and ongoing operational efficiencies.